Abstracts comes from BOT (insulin glargine plus glimepiride and metformine) in comparison to a conventional therapy (CT) with premixed insulin (30/70) twice daily were analysed. METHODS: The applied DMM is an epidemiological simulation model developed to predict the progression of the disease in a simulated diabetes patient population. Baseline values for the simulations: mean age of the population 60 ± 9.0 years, mean duration of diabetes 9.0 ± 7.0 years and mean HbA1c value 8.8 ± 0.9%. The response rate for BOT (HbA1c ≤ 7%) was 49% and for CT 39%. Mean HbA1c for responders were 6.46% and 6.55% respectively, whereas values for non-responders were assumed to be 7.82% and 8.09%. The responder rates in the sensitivity analyses were varied in 2%-steps, with a range between 44% and 56%. Additionally the impact of age/duration variations was analysed. RESULTS: The relative risk reduction (RRR) for micro vascular events after 10 simulation years for BOT versus CT cohort varied between 14% (ESRD) and 2% (retinopathy). The sensitivity analysis showed that also with a worst-case scenario (i.e. BOT responder-rate of 44%) the RRR for ESRD was still in the range of 10%. Patient stratification on age and duration demonstrated that the response-rates had the strongest influence on diabetes complications of kidneys and nerve system, especially in the earlier stages of diabetes. CONCLUSIONS: Better HbA1c control with BOT compared to CT is estimated to reduce long-term micro-vascular complications based on simulations with the DMM. Cardiff University, Cardiff, South Glamorgan, UK, 2 Cardiff Research Consortium, Cardiff, South Glamorgan, UK, 3 sanofi-aventis UK, Guildford, Surrey, UK OBJECTIVES: The purpose of this study was to measure the relative outcome of treatment following initiation of treatment with insulin glargine versus insulin detemir in General Practice in people with both type 1 (T1DM) and type 2 (T2DM) diabetes mellitus. METHODS: Data were extracted from a proprietary database of primary care records (THIN). Cases were selected if treated exclusively with either glargine or detemir. Glycaemic control (HbA 1c ) was extracted for up to nine months following basal analog initiation and averaged over three quarterly periods, given the recent launch of detemir. Records of GP contacts for hypoglycaemia were also examined. RESULTS: There were 4844 subjects available for analysis in the glargine group and 528 subjects in the detemir group; baseline cohort characteristics were equivalent. In T1DM the glargine and detemir groups compared respectively: 40. Following switching, diabetes control was superior in T1DM when treated with glargine; the mean reduction in HbA 1c using glargine compared to baseline was 0.19%, 0.36%, and 0.37% for Q1 to Q3, respectively (p < 0.01). A similar pattern was evident in T2DM, where the improvement was 0.52%, 0.82%, and 0.89%, respectively (p < 0.001). There were fewer reports of GP-treated hypoglycaemia episodes with glargine vs. detemir (4.80 per 100 patient years [PHPY] vs. 6.40 PHPY; p < 0.05). CONCLUSIONS: When used in general practice, glargine resulted in superior glycaemic control and fewer hypoglycaemic episodes than detemir in both Type 1 and Type 2 diabetes.
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